Clinical trials: Non Hodgkin Lymphoma
Psoriasis
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01276639
- Testing
- CP-690,550
- Where
- 74 sites in United States, Canada and 9 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD)…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04970901
- Testing
- Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab
- Where
- 40 sites in United States, Belgium and 4 more
- Volunteers
- 154 people
- Sponsor
- ADC Therapeutics S.A.
Lymphoma, Mantle-Cell
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) remains difficult to treat by standard treatment approaches. Novel drugs have shown promising results in early clinical evaluations.
- Trial name
- NCT00261612
- Testing
- bortezomib, rituximab, dexamethasone
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Medical University of Vienna
Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.
- Trial name
- NCT04532281
- Testing
- Murine CD19 CAR-T cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This is a modular study of AZD2014 in combination with novel anti-cancer agents in patients with different subtypes of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- INHIBITOR (NCT02780830)
- Testing
- AZD2014, Ibrutinib
- Sponsor
- AstraZeneca
Lymphoma, Lymphoma, B-Cell
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06693830
- Testing
- Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Hua-Jay J Cherng, MD
B-cell Acute Lymphoblastic Leukemia
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
In the proposed study, escalating doses of inotuzumab ozogamicin will be added to a standard pediatric inspired re-induction regimen and administered to patients with relapsed or refractory B-cell acute lymphoblastic leukemia…
- Trial name
- ALL-001 (NCT03962465)
- Testing
- Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Virginia
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical…
- Trial name
- NCT03117036
- Testing
- Chemotherapy
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Non-Hodgkin Lymphoma
Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)
To evaluate the use of ibritumomab tiuxetan (Zevalin) as part of the non myeloablative conditioning with melphalan, fludarabine and thiotepa in patients submitted to allogeneic transplantation of haematopoietic stem cells from…
- Trial name
- Z-RIC-Allo (NCT00644371)
- Testing
- Ibritumomab Tiuxetan (Zevalin)
- Where
- 14 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Relapsed Non Hodgkin Lymphoma, Refractory Lymphoma
Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma
This study enrolled patients with relapsed or refractory diffuse large B cell lymphoma treated with polatuzumab vedotin-based chemoimmunotherapies.
- Trial name
- NCT05006534
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Hematologic Malignancy
Besponsa Post Marketing Surveillance Study
Besponsa is approved for the treatment of R/R B-cell ALL in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS.
- Trial name
- NCT04307134
- Testing
- Inotuzumab ozogamicin
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Pfizer
Chronic Lymphoid Leukemia, Lymphoid Malignancies
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
The Phase 1 portion of the study evaluated the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose in subjects with lymphoid malignancies.
- Conditions
- Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma
- Trial name
- NCT00406809
- Testing
- ABT-263
- Where
- 12 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Multiple Myeloma, Non-Hodgkin Lymphoma
Music Therapy on Nausea and Pain for Autologous Stem Cell
Autologous stem cell transplant (ASCT) is an important therapy for patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. It has been shown to improve progression free survival and overall survival.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT01487031
- Testing
- Music Therapy, No music therapy
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Case Comprehensive Cancer Center
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma
Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
- Trial name
- NCT00003502
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Leukemia, B-Cell
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and clinical activity of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in treating patients with recurrent or refractory CD19 positive B cell ccute lymphoblastic…
- Trial name
- NCT03599375
- Testing
- CD19-targeted CART cells
- Volunteers
- 20 people
- Sponsor
- jiuwei cui
Lymphoma
Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00104819
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim
- Where
- 51 sites in United States
- Volunteers
- 238 people
- Sponsor
- Favrille
Lymphoma, B-Cell, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies.
- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT03162536
- Testing
- Nemtabrutinib
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
This is a Phase 1, first-in-human (FIH), open-label, multicenter, study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise…
- Conditions
- T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Recurrent
- Trial name
- NCT04712864
- Testing
- LB1901
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Legend Biotech USA Inc
Lymphoma, Large B-Cell, Diffuse, Stage III Follicular Lymphoma
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
The study is to evaluate the therapeutic effect of metformin as a maintenance therapy in high risk patients with complete remission of diffuse large B lymphoma / stage III follicular lymphoma after chemotherapy in the initial…
- Trial name
- NCT03600363
- Testing
- Metformin
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Ruijin Hospital
Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma
Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac events.
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Toxicity, Cardiac
- Trial name
- Cardiocare (NCT03480087)
- Where
- Italy
- Volunteers
- 118 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.